2Charlap S,Lichstein E,William H,et al.Adrenergic blocking drugs in the treatment of congestive heart failure.Med Clin North Am,1989,73(2):373.
3Krum HH.β-blockers for mild to moderate heart failure.Lancet,1999,353(9146):2.
二级参考文献1
1Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
7Wolff AA, Rotmensch HH, Stanley WC, et al. Metabolic appreaches to the treatment of ischemie heart disease: the clinicimm' perspective[J].Heart Fail Rev, 2002, 7(2) : 187-203.
8Kantor PF, Lueien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to gluc08e oxidation by inhibiting rnitoehondrial long-chain 3-ketoacyl coenzyme A thiolase[J]. Circ Res, 2000, 86(5):580-588.
9Demaison L' Fantini E, Sentex E, et al. Trimetazidine: in vitro influence on heart mitochondrial function[J].Am J Cardiol, 1995, 76(6): 31B-37B.
10Renaud/g. Internal pH, Na +, and Ca2 + regulation by trimetazidine during cardiac cell acidosis[J]. Cardiovaac Drugs Ther, 1988, 1 ( 6 ) : 67%686.
